Pathogenicity and virulence of Mycobacterium tuberculosis

KC Rahlwes, BRS Dias, PC Campos… - Virulence, 2023 - Taylor & Francis
Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis, an infectious
disease with one of the highest morbidity and mortality rates worldwide. Leveraging its …

Abrasive-based nano-finishing techniques: an overview

VK Jain - Machining Science and Technology, 2008 - Taylor & Francis
The surface finishing techniques can be divided into two categories: traditional and
advanced. To overcome some of the problems of traditional finishing techniques, hybridized …

[HTML][HTML] Tuberculosis pathophysiology and anti-VEGF intervention

DP Maison - Journal of Clinical Tuberculosis and Other …, 2022 - Elsevier
The pathophysiological understanding of tuberculosis is growing, and with this growth
comes the possibility of applying established pharmaceuticals in new ways. These new …

Virtual screening, optimization and molecular dynamics analyses highlighting a pyrrolo [1, 2-a] quinazoline derivative as a potential inhibitor of DNA gyrase B of …

JMC Arévalo, JC Amorim - Scientific Reports, 2022 - nature.com
Tuberculosis is a disease that remains a significant threat to public health worldwide, and
this is mainly due to the selection of strains increasingly resistant to Mycobacterium …

Mycobacterial β-carbonic anhydrases: Molecular biology, role in the pathogenesis of tuberculosis and inhibition studies

J Parkkinen, R Bhowmik, M Tolvanen, F Carta… - Enzymes, 2024 - books.google.com
1. Introduction 2. Computational tools for studying M. tuberculosis β-carbonic anhydrases 3.
Molecular biology 4. β-CA1 is induced during environmental stress 5. β-CA2 is essential for …

Emerging insight of whole genome sequencing coupled with protein structure prediction into the pyrazinamide-resistance signature of Mycobacterium tuberculosis

CK Huang, MC Yu, CS Hung, JC Lin - International Journal of Antimicrobial …, 2024 - Elsevier
Pyrazinamide (PZA) is considered to be a pivotal drug to shorten the treatment of both drug-
susceptible and drug-resistant tuberculosis, but its use is challenged by the reliability of drug …

Complementary supramolecular drug associates in perfecting the multidrug therapy against multidrug resistant bacteria

P Sahoo - Frontiers in Immunology, 2024 - frontiersin.org
The inappropriate and inconsistent use of antibiotics in combating multidrug-resistant
bacteria exacerbates their drug resistance through a few distinct pathways. Firstly, these …

Three enigmatic BioH isoenzymes are programmed in the early stage of mycobacterial biotin synthesis, an attractive anti-TB drug target

Y Xu, J Yang, W Li, S Song, Y Shi, L Wu, J Sun… - PLoS …, 2022 - journals.plos.org
Tuberculosis (TB) is one of the leading infectious diseases of global concern, and one
quarter of the world's population are TB carriers. Biotin metabolism appears to be an …

Recent progress in the development of novel mycobacterium cell wall inhibitor to combat drug-resistant tuberculosis

TM Belete - Microbiology Insights, 2022 - journals.sagepub.com
Despite decades of research in drug development against TB, it is still the leading cause of
death due to infectious diseases. The long treatment duration, patient noncompliance …

The oxidation of cholesterol derivatives by the CYP124 and CYP142 enzymes from Mycobacterium marinum

A Ghith, JB Bruning, SG Bell - The Journal of Steroid Biochemistry and …, 2023 - Elsevier
The CYP124 and CYP142 families of bacterial cytochrome P450 monooxygenases (CYPs),
catalyze the oxidation of methyl branched lipids, including cholesterol, as one of the initial …